We had previously shown that murine macrophages expressing v-Fes, the oncogenically activated counterpart of the c-Fes cytoplasmic tyrosine kinase, proliferate independently of Macrophage Colony-Stimulating Factor (MCSF) and that the Extracellular signal-Regulated Kinase (ERK) pathway mediates the mitogenic eect of v-Fes. In this study, the response of c-fes-and v-fesoverexpressing cells to MCSF was investigated. A critical modulation of the activation of Mitogenactivated ERK Kinase (MEK) and ERK based on the MCSF dose was characterized. ERK activation was increased by MCSF doses capable to elicit a mitogenic response (2 ± 5 U/ml). On the contrary, MCSF doses as low as 0.05 U/ml markedly reduced ERK phosphorylation and nuclear content and moderately but signi®cantly reduced cell proliferation. The reduction of MEK and ERK phosphorylation was very rapid, suggesting the involvement of cytosolic phosphatases. Among these, phospho ± tyrosine protein phosphatases and phosphoserine/threonine protein phosphatase-2A were found involved. These ®ndings represent the ®rst observation that dierent doses of the same growth factor, MCSF in particular, can exert opposite eects on cell proliferation by switching on or o ERK signaling.
Introduction
ERK1 and ERK2, members of the Mitogen-Activated Protein Kinase (MAPK) family, are activated in many cell types in response to a variety of stimuli. The best characterized MAPK cascade includes the sequential activation of Ras, Raf, MEK and ERK. Active Raf phosphorylates and activates the dual-speci®city kinases MEK1 and MEK2, which, in turn, activate ERK1 and ERK2, respectively (reviewed in Kolch, 2000) . In unstimulated cells, ERK1 and ERK2 are mostly located in the cytosol; upon phosphorylation, both proteins translocate to the nucleus (Chen et al., 1992a; Lenormand et al., 1993) to phosphorylate a number of transcription factors, Elk-1 being the best characterized example (Gille et al., 1992; Marais et al., 1993) . Speci®c biological eects of ERKs have been linked to the time-course of their activation. PC12 cells, for instance, proliferate in response to the treatment with epidermal growth factor or dierentiate with nerve growth factor, depending on the time-course of ERK activation (reviewed in Marshall, 1995) . In macrophages, proliferating agents (i.e. MCSF, Granulocyte/Macrophage-CSF, Interleukin-3 or tetradecanoyl-phorbol-myristate-acetate) elicit rapid ERK activation, peaking at 3 ± 5 min, while dierentiating factors (lipopolysaccharide, phosphatidylcholine-speci®c phospholipase-C), which block proliferation and induce dierentiation or production of in¯ammatory cytockines, activate ERK with slower kinetics, peaking at 15 min Jaworowski et al., 1996; Valledor et al., 2000) . MEK inhibition by PD98059 is able to block all these responses. By contrast, we show in this study that the same growth factor, namely MCSF, depending on the dose supplied, can elicit either ERK activation or inhibition, thereby promoting or inhibiting cell proliferation, respectively.
Dephosphorylation of either the threonine or tyrosine residue alone within the TXY motif in the MAPK activation loop results in the enzymatic inactivation of ERKs. In intact cells, MAPK dephosphorylation occurs with a kinetics ranging from minutes to several hours, depending on cell type and activating stimulus. In PC12 cells stimulated by epidermal growth factor, ERK undergoes an early and rapid inactivation, re¯ecting in part phospho ± threonine dephosphorylation by PP2A (Alessi et al., 1995) . PTPs also contribute to ERKs inactivation (Alessi et al., 1995) . Among these, the dual-speci®city phosphatases are a PTP subclass which dephosphorylates both phospho ± tyrosine and phospho ± threonine residues (Camps et al., 2000) .
The c-fes/fps proto-oncogene encodes for a 92 kDa non-receptor protein tyrosine kinase (p92 c-fes ) that is expressed in myeloid and endothelial cells (Smithgall et al., 1998) . The overexpression of c-fes or v-fes in BAC-1.2F5 murine macrophages, which depend on MCSF for survival and growth, results in MCSF-independent growth (Areces et al., 1994; Rovida et al., 2000) . We recently demonstrated that v-fes-expressing macrophages exhibit a constitutively increased phosphorylation of ERK1/2 and MEK, paralleled by a constitutive localization of ERK in the nucleus. Treatment of v-fesexpressing cells with the MEK inhibitor PD98059 markedly reduced cell growth and the hyperphosphorylation and nuclear localization of ERK, indicating that the ERK pathway mediates the mitogenic eect of v-fes (Rovida et al., 2000) . In the study reported here, MCSF-induced mitogenesis in fes-overexpressing cells was paralled by a further increase of MEK/ERK phosphorylation and activation. On the other hand, low doses of MCSF determined a marked, rapid decrease of ERK phosphorylation and nuclear localization, paralleled by a moderate but signi®cant decrease of cell proliferation. Thus, the constitutively high ERK phosphorylation in fes-overexpressing cells allowed detection, for the ®rst time, of concentrationdependent opposite eects of a growth factor, MCSF in particular, on ERK phosphorylation and cell proliferation.
Results
In c-fes-as well, as expected (Rovida et al., 2000) , vfes-overexpressing cells, basal ERK/MEK phosphorylation was increased with respect to that of control (KB) cells (Figure 1a) . In all fes-overexpressing clones tested, a 5-min treatment with a mitogenic dose (5 U/ ml) of MCSF determined a further, marked increase of ERK and MEK phosphorylation, under conditions where ERK and MEK levels were unchanged. The kinetics of ERK activation following treatment with 5 U/ml MCSF in v-fes-and c-fes-overexpressing cells showed a peak of ERK phosphorylation at 3 ± 5 min, as observed in KB cells (Figure 1b ) and in normal macrophages Jaworowski et al., 1996; Valledor et al., 2000) .
We next analysed the dependence of ERK phosphorylation on the MCSF dose and found that mitogenic doses (2 ± 5 U/ml) increased ERK phosphorylation with respect to unstimulated cells, while doses of MCSF as low as 0.05 U/ml decreased ERK phosphorylation (Figure 2a ). The eect of 0.05 U/ml MCSF on ERK and MEK phosphorylation was con®rmed in several fes-overexpressing clones (Figure 2b ).
The kinetics of ERK and MEK phosphorylation in v-fes-expressing cells following the treatment with 0.05 U/ml MCSF is shown in Figure 3 . The decrease of phosphorylation was already evident after 1 min MCSF treatment and was followed by a marked increase peaking at 20 min, to decrease again thereafter.
The rapid kinetics of the reduction of ERK and MEK phosphorylation determined by 0.05 U/ml MCSF in fes-overexpressing cells suggested the involvement of an MCSF-activated phosphatase. In this respect, it is known that PP2A activation is maximal after a 2-min MCSF treatment and that, following growth factor stimulation, PP2A can be inactivated within 5 ± 15 min (Chen et al., 1992b (Chen et al., , 1994 . The involvement of PP2A was tested by pretreating cells with okadaic acid at concentrations speci®cally inhibiting PP2A (Favre et al., 1997) . Okadaic acid partially prevented the MCSF-dependent reduction of ERK phosphorylation, indicating that PP2A is involved in this reduction. PTPs are also involved, as the pretreatment of cells with phenylarsine oxide and orthovanadate completely prevented ERK dephosphorylation (Figure 4 ). The involvement of phospho-tyrosine dephosphorylation is, however, supported by the fact that all the data reported in Figures 1 ± 4 were obtained not only by using the anti-phosphothr/tyr-ERK antibodies, but also with antibodies exclusively directed to the phospho-tyr residues of ERK (not shown). Figure 1 Eects of a mitogenic MCSF dose on ERK and MEK phosphorylation in fes-overexpressing cells. KB, VFB1 or CFB16 cells were incubated for 16 ± 18 h in DMEM supplemented with 10% FBS, treated or not with 5 U/ml human recombinant MCSF for 5 min (a) or the indicated times (b) and lysed. Equal amounts of proteins were separated by SDS ± PAGE in a 12.5% gel and immunoblotted with polyclonal a-phosphoERK1/2 (pERK1/2) or a-phosphoMEK (pMEK) antibodies and, after stripping, a-ERK or a-MEK antibodies As ERK phosphorylation is related to mitogenesis in macrophages (Valledor et al., 2000; Rovida et al., 2000) , we determined the eects of dierent doses of MCSF on the numbers of either v-fes-or c-fesoverexpressing cells in culture after a 3-day treatment. Cell numbers were found increased with 2 or 5 U/ml MCSF with respect to unstimulated controls, and moderately, but signi®cantly, reduced with 0.05 U/ml ( Figure 5a ). These results were con®rmed by cytouorimetry. Indeed, an increase or a reduction of DNA-bound propidium iodide¯uorescence, re¯ecting the percentage of cells in the S phase of cell cycle, always paralleled the eects of dierent doses of MCSF on cell numbers ( Figure 5b ). The relationship between ERK phosphorylation and mitogenesis was con®rmed by immuno¯uores-cence ( Figure 6 ). Treatment of control cells with 5 U/ ml MCSF determined an accumulation of ERK in the nucleus, as revealed by both ERK and pERK staining ( Figure 6 ). The constitutively high nuclear content of ERK in v-fes overexpressing cells (Rovida et al., 2000) was further increased following treatment with 5 U/ml MCSF ( Figure 6 ). On the contrary, 0.05 U/ml MCSF determined a redistribution of ERK from the nucleus to the cytoplasm ( Figure 6 ). Identical results were obtained with pERK staining (Figure 6 ). It is worth pointing out here that the treatment with 0.05 U/ml determined the disappearance of pERK, in keeping with the results of Figure  2b Equal amounts of proteins were separated by SDS ± PAGE in a 12.5% gel and immunoblotted with polyclonal a-phosphoERK1/2 (pERK1/2) or a-phosphoMEK (pMEK) antibodies and, after stripping, a-ERK or a-MEK antibodies. The pERK1 and pERK2 densitometry values tabled in (a) were normalized with respect to the ERK1 or ERK2 content and are reported in function of the respective value of unstimulated cells Figure 3 Kinetics of ERK and MEK phosphorylation in response to a low MCSF dose. VFB1 cells were incubated for 16 ± 18 h in DMEM supplemented with 10% FBS, treated with 0.05 U/ml human recombinant MCSF for the indicated times and lysed. Equal amounts of proteins were separated by SDS ± PAGE in a 12.5% gel and immunoblotted with polyclonal a-phosphoERK1/2 (pERK1/2) or a-phosphoMEK (pMEK) antibodies and, after stripping, an a-ERK1/2 antibody. The pERK1 (dashed line), pERK2 (bold dashed line) and pMEK (continuous line) densitometry values shown in the graph were normalized with respect to the ERK1 content and are reported in function of the respective time-zero value Figure 4 Eect of okadaic acid or phenylarsine oxide plus natrium orthovanadate on ERK dephosphorylation elicited by a low MCSF dose. VFB1 cells were incubated for 16 ± 18 h in DMEM supplemented with 10% FBS and treated with okadaic acid (OKA, 100 nM, 45 min) or phenylarsine oxide (PAO, 20 mM, 30 min) plus natrium orthovanadate (OVA, 2 mM, 10 min). Cells were then stimulated or not for 5 min with 0.05 U/ml human recombinant MCSF and lysed. Equal amounts of proteins were separated by SDS ± PAGE in a 12.5% gel and immunoblotted with a polyclonal a-phosphoERK1/2 (pERK1/2) and, after stripping, a-ERK1/2 antibody. The pERK1 and pERK2 densitometry values shown in the table were normalized with respect to the ERK1 or ERK2 content and reported in function of the respective value of unstimulated cells
Discussion
The MEK/ERK pathway plays an important role in the proliferation of normal macrophages in response to MCSF (Jaworowski et al., 1999; Valledor et al., 2000) , as well as in MCSF-independent growth due to v-fes expression (Rovida et al., 2000) . To exclude that the constitutive ERK activation in v-fes-expressing cells were a consequence of the expression of v-Fes rather than Fes itself, an increase of ERK phosphorylation with respect to mock-infected controls was con®rmed in several c-fes-overexpressing clones, which also exhibit an MCSF-independent growth (Areces et al., 1994) . In both v-fes-and c-fes-overexpressing cells, despite the constitutive ERK activation, the proliferative response elicited by MCSF was paralleled by a further increase of ERK phosphorylation, which occurs with a typical time-course, characterized by a peak at 3 ± 5 min following MCSF treatment, as in normal macrophages. The proliferative response to MCSF was also paralleled by a further increase of ERK and pERK nuclear localization. Thus, the mitogenic response of fes-overexpressing cells to MCSF occurs with a typical pattern of ERK activation. Yet fesoverexpressing cells are characterized by a higher-thannormal basal level of ERK activation. In this system, a low dose of MCSF determined a marked and rapid decrease of ERK phosphorylation and nuclear content, allowing to detect a previously unknown ability of MCSF of down-regulating ERK activation. These eects on ERK of a low MCSF dose were paralleled by a moderate but signi®cant inhibition of cell number increase. We want to stress here that, although the eect on proliferation as revealed by measuring cell number was not marked, we were able to con®rm this eect in another set of experiments by evidencing a reduction of cell transition to the S phase of cell cycle. Thus, the decrease of nuclear ERK determined by lowdose MCSF likely resulted in the shut-o of genes whose products are necessary for cell proliferation and/ or for counteracting apoptosis.
The results presented here, while further supporting the relationship between ERK phosphorylation and mitogenesis in macrophages, show that dierent doses of the same growth factor are capable to determine opposite eects on cell proliferation via the activation or inhibition of ERK. Thus, a new mechanism of regulation of cell functions emerges, based on the critical modulation of ERK activity by varying the dose of the same stimulator within the same time-frame of stimulation. This type of modulation can now be added to that observed in other experimental systems (Marshall, 1995) which drives dierent biological responses on the basis of transient vs sustained ERK activation. This eect may be also relevant to cell functions other than proliferation, such as macrophage dierentiation or activation.
The rapid kinetics of ERK dephosphorylation (evident after 1 min) that occurs upon low-dose MCSF treatment does not seem compatible with an even quick arrest of kinase activity, thus suggesting the involvement of one or more phosphatases. ERK dephosphorylation was, indeed, paralleled by MEK dephosphorylation. This suggests the following hypotheses, which are not mutually exclusive: (a) phospho-MEK and phospho-ERK are dephosphorylated in parallel by the same MCSF-activated phosphatase(s); (b) the MCSF-activated phosphatase(s) dephosphorylate MEK, preventing the MEK-dependent phosphorylation of ERK, which would be dephosphorylated by other phosphatases, activated by MCSF or constitutively. In any case, the rapid dephosphorylation of both phospho-MEK and phospho-ERK indicates the involvement of phosphatase(s) acting directly on either of these kinases. Among many candidates, PP2A and PTPs were found involved. The sensitivity of the eect of low-dose MCSF on MEK/ERK phosphorylation to okadaic acid points to the involvement of PP2A, which is in keeping with previous results: (a) ERK is a well known substrate of PP2A (Alessi et al., 1995; Anderson et al., 1990) ; (b) PP2A is activated in bone marrowderived macrophages within 2 min of stimulation with MCSF , a kinetics compatible with our data on ERK dephosphorylation; (c) PP2A can be inactivated after 5 ± 15 min of growth factor stimulation (Chen et al., 1992b (Chen et al., , 1994 , a fact that well explains the increase of ERK phosphorylation we found after a 20 ± 30-min treatment with a low dose of MCSF. On the other hand, we found that PTP inhibitors can prevent the phospho-ERK dephosphorylation induced by low-dose MCSF. Among PTPs, SHP1 has been shown to be activated by MCSFR (Yeung et al., 1992) , but dual-speci®city phosphatases are more likely involved, the cytosolic MKP3 in particular, which we found constitutively expressed in fes-overexpressing macrophages, as well as parental cells (data not shown). It is worth noting here that the overexpression of v-raf, eliciting, like that of fes, the MCSFindependent growth of BAC macrophages (BuÈ scher et al., 1993) , determines a constitutive expression of MKP1 . Thus, it is conceivable that in fes-overexpressing macrophages some phosphatases are constitutively more susceptible to activation by even low doses of MCSF which are, on the contrary, unable to stimulate MEK and ERK activity. In the absence of MCSF, as well as in the presence of a mitogenic MCSF dose, MAPK phosphorylation would be favored, while low-dose MCSF would alter the balance towards dephosphorylation, resulting in MAPK inactivation. The eects of PP2A and PTP inhibitors on the proliferative response to MCSF could not be revealed in our system, due to the known direct interference of either okadaic acid or orthovanadate with cell growth (Klarlund, 1985; Feldman et al., 1990; Wilson et al., 1999) .
The data reported in this paper support our hypothesis that the Fes-generated proliferative stimuli and those elicited by activated MCSFR are conveyed via at least partially overlapping signal transduction pathways. MCSFR itself may actually represent the point at which the two pathways converge, as fesoverexpressing cells exhibit a constitutive shift of the MCSFR electrophoretic band (data not shown). This suggests that Fes lie upstream MCSFR and that a constitutive MCSFR phosphorylation ultimately determine the MCSF-independent growth of these cells. Accordingly, the constitutive ERK activation in fesoverexpressing cells would occur via MCSFR, well explaining the interference of MCSF on ERK phosphorylation. Thus, our study contributes to the understanding of Fes-dependent signaling in macrophages, as well as of the involvement of MEK/ERK in macrophage growth.
Our system, based on Fes overexpression, although unlikely to re¯ect physiology of normal cells, most probably mimics a situation occurring in nature in neoplastic cells. On the other hand, due to the exponential decay kinetics of even high doses of MCSF injected in vivo, doses as low as 0.05 U/ml are surely reached in biological¯uids. The biological relevance of our ®ndings lies in the demonstration that such low doses of MCSF are capable of triggering signals eliciting detectable biological eects. Furthermore, our results de®nitively linked ERK phosphorylation to macrophage proliferation, demonstrating that an increased proliferation is paralleled by ERK activation, while a decreased proliferation is paralleled by ERK inhibition, Figure 6 Eect of a low MCSF dose on the nuclear localization of ERK. KB (a) or VFB1 (b) cells were incubated for 16 ± 18 h in DMEM supplemented with 10% FBS and treated, where indicated, with phenylarsine oxide (PAO, 20 mM, 30 min) plus natrium orthovanadate (OVA, 2 mM, 10 min). Cells were then stimulated for 90 min with the indicated doses (U/ml) of human recombinant MCSF. Immunostaining was performed with a-ERK or a-phosphoERK followed by Cy3-conjugated a-rabbit antibody and, last but not the least, that both these eects are liable to be determined by the same growth factor.
Materials and methods

Cells and cell culture
Murine macrophages of the BAC-1.2F5 cell line, which depends on MCSF for survival and proliferation (Morgan et al., 1987) , were infected with a helper virus (amphotropicMuLV) alone, to obtain`mock infected' cells (KB cells), or carrying a pHFeSV plasmid containing v-fes (v-fes-overexpressing BAC clones; VFB clones) or c-fes (CFB clones), as already described (Rovida et al., 2000; Areces et al., 1994; Feldman et al., 1989) . Cells were cultured in DMEM (EuroClone) supplemented with 4 mM glutamine (EuroClone), 10% FBS (EuroClone) and murine recombinant MCSF.
Growth factors
Cells were routinely cultured in the presence of 6 ng/ml murine recombinant, anity-puri®ed MCSF (Krautwald and Baccarini, 1993) ; all the experiments were performed with human recombinant MCSF (Pepro Tech), 5 ng/ml of which (speci®c activity: 2610 5 Units/mg) represents the ED 50 , as determined by the dose-dependent stimulation of the proliferation of murine M-NFS-60 cells.
Determination of cell growth
Cells were seeded (10 000 cells/well in 96-well plates) in DMEM supplemented with 10% FBS, in the absence or the presence of human recombinant MCSF. After a 3-day incubation, the medium was removed and cells were ®xed with 10% ice-cold trichloroacetic acid for 1 h at 48C. Cell monolayers were washed 5 ± 6 times with water and allowed to dry. A sulforodamine-B (Sigma, cat.no. S-1402) solution (0.4% in 1% acetic acid) was then added for 30 min at RT. Cell monolayers were washed 5 ± 6 times with 1% acetic acid and allowed to dry. The cell-bound sulforodamine-B was solubilized in 150 ml/well 10 mM Tris and the light absorbance of this solution spectrophotometrically measured (wave-length: 595 nm). Cell numbers corresponding to the absorbance values were calculated according to a standard titration curve. Cell numbers determined 3 h after plating (time necessary for cell adhesion to occur) were considered as time-zero values.
Cytofluorimetry
Cells were incubated for 48 h in DMEM supplemented with 10% FBS and then for 40 h either in the absence or the presence of human recombinant MCSF. Cells were centrifuged and the pellets resuspended in cold (7208C) 70% ethanol and incubated for 15 min in ice. Pellets were washed twice with PBS containing 0.1% sodium azide and 0.1% BSA, resuspended in PBS containing 0.1% sodium azide, 0.1% BSA, propidium iodide (50 mg/ml) and ribonuclease A, and incubated in the dark (30 min, room temperature). Cyto¯uorimetric analysis was performed with a FACScan (Becton-Dickinson).
Antibodies and inhibitors
Rabbit polyclonal a-phosphoERK1/phosphoERK2 (New England Biolabs, cat.no. 9101), reacting with phosphoThr202 and phospho-Tyr204 of ERK1 and with phosphoThr183 and phospho-Tyr185 of ERK2; mouse monoclonal aphosphoERK1/phosphoERK2 reacting with phospho-Tyr204 of ERK1 and with phospho-Tyr185 of ERK2 (Santa Cruz Inc., cat.no. sc-7383); rabbit polyclonal a-ERK1 (Santa Cruz Inc., cat.no. sc-93), reacting with ERK1 and, to a lower extent, ERK2; rabbit polyclonal a-pMEK1/2 (New England Biolabs, cat.no. 9121), reacting with MEK1/2 only when activated by phosphorylation at Ser217/221; rabbit polyclonal a-MEK1/2 (New England Biolabs, cat.no. 9122); a-mouse IgG and a-rabbit IgG, horseradish peroxidase (HRP)-conjugated, as secondary antibodies for immunoblotting (Sigma, cat.no. A-4416 and A-6154 respectively); a-rabbit IgG, Cy3-conjugated, as secondary antibody for immunostaining (Chemicon International, cat. no AP182C). Inhibitors (target, ®nal concentration, time before MCSF stimulation): okadaic acid (PP2A, 100 nM, 45 min; Calbiochem); natrium orthovanadate (PTP, 2 mM, 10 min; SIGMA); phenylarsine oxide (PTP, 20 mM, 30 min).
Determination of ERK1/2 and MEK expression and phosphorylation
Cells were incubated for 16 ± 18 h in DMEM supplemented with 10% FBS and then stimulated or not with human recombinant MCSF as indicated. Culture plates were placed on ice, cell monolayers rapidly washed three times with icecold PBS containing 100 mM orthovanadate and cells removed by scraping in 1 ml ice-cold PBS containing 100 mM orthovanadate and collected by centrifugation (300 g, 10 min, 48C). Cell pellets were solubilized in ice-cold lysis buer (5 mM EDTA, 50 mM NaCl, Tris 10 mM, 1% Triton X-100, 50 mM NaF, 30 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 , 1 mM PMSF, 0.1 U/ml aprotinin, 4 mg/ml pepstatin A and 10 mg/ml TPCK) and Triton-insoluble material removed by centrifugation (20 000 g630 min, 48C). Protein concentration in supernatants was determined and 30 mg aliquots of each sample were diluted with 46Laemmli buer and boiled for 10 min in the presence of 100 mM 2-mercaptoethanol. Proteins were separated by SDS ± PAGE in 12.5% minigels and then transferred onto nitrocellulose membranes (Hybond-ECL, Amersham) by electroblotting. To determine ERK1/2 phosphorylation, membranes were blocked in PBS containing 0.1% Tween-20 and 1% BSA (T-PBS/1%BSA; 3 ± 5 h, RT), incubated in a 1 : 1000 dilution of rabbit a-pERK in T-PBS/ 1%BSA (16 ± 18 h, 48C) and then in a 1 : 5000 dilution of HRP-conjugated anti-rabbit IgG in T-PBS/2%BSA (1 h, 48C). Antibody-coated protein bands were visualized by ECL chemiluminescence detection (Amersham). To determine ERK1/2 expression, membranes were stripped, blocked and reprobed by incubation in a 1 : 1000 dilution of rabbit a-ERK in T-PBS/5%BSA (1 h, RT) and then in a 1 : 5000 dilution of HRP-conjugated a-rabbit IgG in T-PBS/2%BSA (1 h, RT). To determine MEK phosphorylation membranes were blocked in T-PBS/1%BSA (3 ± 5 h, RT), incubated in a 1 : 1000 dilution of rabbit a-phospho-MEK1/2 in T-PBS/1%BSA (16 ± 18 h, RT) and then in a 1 : 5000 dilution of HRP-conjugated antirabbit IgG in T-PBS/2%BSA (1 h, RT). To determine MEK expression, membranes were stripped, blocked and reprobed by incubation in a 1 : 1000 dilution of rabbit a-MEK1/2 in T-PBS/5%BSA (1 h, RT) and then in a 1 : 5000 dilution of HRPconjugated a-rabbit IgG in T-PBS/2%BSA (1 h, RT).
Immunocytochemistry
Cells were seeded in 6-well plates, cultured for 24 h in DMEM supplemented with 10% FBS, and either incubated with 0.05 U/ml human recombinant MCSF for 90 min or left Immunocytochemistry was performed as suggested by New England Biolabs with minor modi®cations. Brie¯y, after a wash with PBS, cell monolayers were ®xed by a 20-min incubation at 48C in PBS containing 3% paraformaldehyde. After three washes (5 min each) with PBS containing 1% Triton X-100 (PBST), cells were incubated for 45 ± 60 min in PBST containing 5.5% horse serum (Celbio, cat. no. ECS0090). Cells were then incubated in a 1 : 1000 dilution of rabbit a-ERK or in a 1 : 250 dilution of a-phospho-ERK in PBS/3%BSA (o/n, 48C), washed (2615 min) with PBST and then incubated in a 1 : 250 dilution of Cy3-conjugated arabbit IgG in PBST/3%BSA (1 h, RT). Cells were ®nally washed (365 min) with PBST and examined by epi¯uores-cence with excitation-emission ®lters for rhodamine. Fluorescence speci®city was checked by: (a) ®xing cells with 4% paraformaldehyde (20 min, RT) or with methanol/acetone (3 : 7 vol/vol, 10 min, 7208C), which produced the same results (not shown); (b) incubating with secondary antibody alone, which did not produce any signi®cant¯uorescence (not shown).
